Risks
4 risks
Risk Intelligence
Warrant conversion risk at unfavorable price
View Risks →Best Agrolife Limited — Q3 FY26
Best Agrolife reported a weak Q3 FY26 with revenue of 202.9 crore, down 26% YoY, due to excessive rainfall and low pest pressure disrupting crop cycles.
bearish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Best Agrolife reported a weak Q3 FY26 with revenue of 202.9 crore, down 26% YoY, due to excessive rainfall and low pest pressure disrupting crop cycles. EBITDA turned positive at 3.8 crore (1.9% margin), improving from a loss last year, but PAT remained a loss of 12.7 crore. The patented portfolio held up relatively well (down only 5%), while generics slumped 48%. Management guided FY26 revenue of 1,300-1,400 crore and expects a return to growth in FY27, targeting 1,500-1,600 crore. Key risks include potential El Niño impact and the conversion of outstanding warrants at a strike price far above the current market price, which could dilute equity if not exercised.
बेस्ट एग्रोलाइफ की तीसरी तिमाही (अक्टूबर-दिसंबर 2025) कमजोर रही। कंपनी की कमाई 202.9 करोड़ रुपये रही, जो पिछले साल से 26% कम है। इसकी वजह ज्यादा बारिश और कीटों का कम प्रकोप था, जिससे फसल चक्र प्रभावित हुआ। कंपनी का परिचालन मुनाफा (EBITDA) 3.8 करोड़ रुपये रहा, जो पिछले साल के नुकसान से बेहतर है। लेकिन शुद्ध लाभ (PAT) में 12.7 करोड़ रुपये का नुकसान हुआ। कंपनी के पेटेंट वाले उत्पादों की बिक्री सिर्फ 5% गिरी, जबकि सामान्य उत्पादों की बिक्री 48% गिर गई। कंपनी को उम्मीद है कि पूरे साल (FY26) में कमाई 1,300-1,400 करोड़ रुपये रहेगी और अगले साल (FY27) में यह बढ़कर 1,500-1,600 करोड़ रुपये हो जाएगी। मुख्य जोखिम हैं: एल नीनो का असर और कंपनी के वारंट (भविष्य में शेयर खरीदने का अधिकार) का इस्तेमाल न होने पर शेयरों की संख्या बढ़ सकती है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Patented portfolio revenue decline
-5%
-5% YoY
Patented products declined only 5% YoY in 9M FY26, showing resilience versus 48% drop in non-patent.
Non-patent portfolio revenue decline
-48%
-48% YoY
Non-patent sales fell 48% in 9M FY26 as company shifted focus to patented products.
New product treated acres
4 lakh acres
N/A (first year)
Each of the two new patented products (Bestman, Pagin) crossed 4 lakh treated acres in their first season.
Sales return reduction
~180 crore
-36% YoY
Sales returns reduced from ~280 crore to ~180 crore in 9M FY26 due to stricter policies.
Fast read
Guidance and risk preview
Management expects full-year FY26 revenue between 1,300 and 1,400 crore, implying Q4 run-rate of 200-300 crore.
Outstanding warrants with exercise price of ~42 rupees (post-split) are far above current market price of ~19 rupees, potentially leading to non-ex...
View Risks →